Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests
- Falagario, Ugo G
- Beksac, Alp Tuna
- Martini, Alberto
- Cumarasamy, Shivaram
- Gupta, Akriti
- Prasad, Sonya
- Thulasidass, Hari
- Shah, Qainat N
- Jayaratna, Isuru
- Lewis, Sara
- Rastinehad, Ardeshir R
- Taouli, Bachir
- Cormio, Luigi
- Carrieri, Giuseppe
- Tewari, Ash K
Publication date
January 2019
DOIAbstract
To determine whether prostate multi parametric MRI (mpMRI) and genomic biomarkers might help further defining patients with favorable intermediate risk patients (FIR) prostate cancer which could safely considered suitable for active surveillance (AS)
Add to ORKG